Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00304278 · ClinicalTrials.gov registry record · Phase 2
Study of RADPLAT and Tarceva in Locally Advanced Head and Neck Squamous Cell Carcinoma (SCCA)
A Phase 2 study, sponsored by Southern Illinois University.
- Completed
- Registry status
- Phase 2
- Development phase
- 21
- Enrollment target
NCT00304278 is a Phase 2 study that has completed, run by Southern Illinois University. The registered enrollment target is 21 participants.
The verdict
NCT00304278, a Phase 2 study, has completed, sponsored by Southern Illinois University.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 21 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the safety and effectiveness of treatment with Tarceva (Erlotinib) and RADPLAT (RADiation and intraarterial cisPLATin) for patients with Head and Neck cancer
Interventions
- DRUG Erlotinib (Tarceva)
- DRUG Intra-arterial Cisplatin (PLAT)
- RADIATION Radiation Therapy (RAD)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 21 participants |
| Start Date | 2006-03 |
| Est. Completion | 2015-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00304278
The ClinicalTrials.gov registry entry for NCT00304278 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 21 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Southern Illinois University, which has 21 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Erlotinib (Tarceva) is the first listed.
NCT00304278 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00304278 about?
NCT00304278 is a clinical study titled "Study of RADPLAT and Tarceva in Locally Advanced Head and Neck Squamous Cell Carcinoma (SCCA)". The purpose of this study is to determine the safety and effectiveness of treatment with Tarceva (Erlotinib) and RADPLAT (RADiation and intraarterial cisPLATin) for patients with Head and Neck cancer
What is the current status of trial NCT00304278?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 21 participants. The study started on 2006-03. Estimated completion is 2015-12.
What interventions are being tested in trial NCT00304278?
The interventions under investigation include: Erlotinib (Tarceva) (DRUG), Intra-arterial Cisplatin (PLAT) (DRUG), Radiation Therapy (RAD) (RADIATION).
Who is sponsoring clinical trial NCT00304278?
This trial is sponsored by Southern Illinois University, which has 21 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.